These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 39068426)
1. Risk prediction model of uterine corpus endometrial carcinoma based on immune-related genes. Sang Q; Yang L; Zhao H; Zhao L; Xu R; Liu H; Ding C; Qin Y; Zhao Y BMC Womens Health; 2024 Jul; 24(1):429. PubMed ID: 39068426 [TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J Front Immunol; 2021; 12():788431. PubMed ID: 34970268 [TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-Associated lncRNA Gene Signature Establishes New Prognostic Profile and Predicts Immunotherapy Response in Endometrial Carcinoma. Jiang XY; Hu JJ; Wang R; Zhang WY; Jin QQ; Yang YT; Mei J; Hong L; Yao H; Tao F; Li JJ; Liu Y; Zhang L; Chen SX; Chen G; Song Y; Zhou SG Biochem Genet; 2024 Oct; 62(5):3439-3466. PubMed ID: 38108937 [TBL] [Abstract][Full Text] [Related]
4. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma. Zhang Q; Luo Y; Zhang S; Huang Q; Liu G Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747 [TBL] [Abstract][Full Text] [Related]
5. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs. Li N; Yu K; Lin Z; Zeng D Exp Biol Med (Maywood); 2022 Feb; 247(3):221-236. PubMed ID: 34704492 [TBL] [Abstract][Full Text] [Related]
6. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma. Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290 [TBL] [Abstract][Full Text] [Related]
7. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs. Zhang X; Ye Z; Xiao G; He T Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773 [TBL] [Abstract][Full Text] [Related]
8. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database. Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565 [TBL] [Abstract][Full Text] [Related]
9. Construction of a microenvironment immune gene model for predicting the prognosis of endometrial cancer. Wang Y; Zhang J; Zhou Y; Li Z; Lv D; Liu Q BMC Cancer; 2021 Nov; 21(1):1203. PubMed ID: 34763648 [TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer. Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523 [TBL] [Abstract][Full Text] [Related]
11. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis. Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma. Jiang N; Li D; Han Y; Luo ZG; Liu LB Aging (Albany NY); 2024 Jun; 16(11):9784-9812. PubMed ID: 38848146 [TBL] [Abstract][Full Text] [Related]
13. The landscape and prognostic value of immune characteristics in uterine corpus endometrial cancer. Liu W; Sun L; Zhang J; Song W; Li M; Wang H Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33782686 [TBL] [Abstract][Full Text] [Related]
14. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma. Niu L; Wu Z Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398 [TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma. Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963 [TBL] [Abstract][Full Text] [Related]
16. Identification of immune-related gene signature for predicting prognosis in uterine corpus endometrial carcinoma. Song S; Gu H; Li J; Yang P; Qi X; Liu J; Zhou J; Li Y; Shu P Sci Rep; 2023 Jun; 13(1):9255. PubMed ID: 37286702 [TBL] [Abstract][Full Text] [Related]
17. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients. Sun XX; Wen HQ; Zhan BX; Yang P Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230 [TBL] [Abstract][Full Text] [Related]
18. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma. Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L Front Oncol; 2022; 12():1030246. PubMed ID: 36439473 [TBL] [Abstract][Full Text] [Related]
19. Effects of HOX family regulator-mediated modification patterns and immunity characteristics on tumor-associated cell type in endometrial cancer. Yang J; Li J; Li S; Yang Y; Su H; Guo H; Lei J; Wang Y; Wen K; Li X; Zhang S; Wang Z Mol Biomed; 2024 Aug; 5(1):32. PubMed ID: 39138733 [TBL] [Abstract][Full Text] [Related]
20. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma. Ouyang D; Li R; Li Y; Zhu X J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]